Preparation method, analysis method and application of solution for detecting allergen activity
By detecting the IgE levels in nasal secretions and serum, and combining statistical analysis methods, the problem of difficulty in monitoring the correlation between local IgE levels and symptoms in the prior art is solved, and a rapid prediction of changes in the symptoms of seasonal allergic rhinitis is achieved. It has significant clinical and economic value.
Patent Information
- Application Number
- CN202411107732.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-13
- Publication Date
- 2024-11-22
- Estimated Expiration
- 2044-08-13
AI Technical Summary
The prior art is difficult to effectively monitor and evaluate the correlation between local IgE levels and symptoms in patients with seasonal allergic rhinitis, resulting in the inability to quickly and timely predict the changes in symptoms under changes in pollen concentration.
Causal mediation analysis was performed to elucidate the changes in IgE levels in nasal secretions and in the pollen by collecting nasal secretions using the ImmunoCAP 100 system and combined with Friedman repeated measurement rank ANOVA, generalized mixed linear model and time series analysis. Mediating role in concentration changes, assessing severity of symptoms.
It has achieved rapid and timely prediction of changes in the symptoms of seasonal allergic rhinitis, which has significant clinical and economic value, and can be used in kits to evaluate the severity of symptoms of seasonal allergic rhinitis.
Smart Images

Figure CN119007833A_ABST
Abstract
Description
Technical Field
[0001] The invention relates to the technical field of immunoassay, and in particular to a preparation method and an analysis method for a solution for detecting allergen activity and an application thereof. Background Art
[0002] Allergic rhinitis (AR) is a type I allergic disease mediated by immunoglobulin E (IgE) that is triggered by the nasal mucosa of atopic individuals after contact with allergens. Among them, seasonal allergic rhinitis (SAR), also known as hay fever, is caused by allergens released by plant pollens, which places a heavy burden on patients and social medical resources. The occurrence and development of allergic reactions are mainly attributed to the continuous excessive production of IgE in response to inhaled allergens (especially pollen). Inhalation of allergens induces the local production of specific IgE (sIgE) in the nasal cavity. Studies have shown that high-affinity IgE in the peripheral blood of sensitized individuals mainly comes from the nasal mucosa and enters the peripheral circulation through the lymphatic vessels. Importantly, allergen sIgE positivity can be detected in the nasal secretions of a portion of subjects with local allergic rhinitis who are serum allergen sIgE negative. These findings suggest that mucosal IgE synthesis can occur in the absence of systemic atopy and may be more responsive to allergens than serum sIgE.
[0003] Therefore, it is very important to clarify the correlation between seasonal pollen concentration, serum and nasal secretion IgE levels and SAR allergy symptoms and medication scores. The present invention aims to explore the correlation between the fluctuation of local IgE levels under natural allergen exposure and the monitoring and evaluation of SAR symptoms. Summary of the invention
[0004] In a first aspect, the present invention provides a method for preparing a solution for detecting allergen activity, the method comprising the following steps:
[0005] S1 Collection preparation: Before collecting nasal secretions, ensure that the subject is in a resting state and comfortable environment;
[0006] S2 collection and processing: two cotton pads were placed in the left and right middle nasal passages of the subjects with forceps, attached to the nasal mucosa, and left for 5 to 10 minutes;
[0007] S3 drying treatment: take the cotton pad out of the nasal cavity and place it in a tray with grooves, mark it; place the tray in a dryer set at 35℃~40℃ for 2~2.5 hours;
[0008] S4 centrifugal pretreatment, after drying, put the cotton pieces into 1.5 mL EP tubes, add 500 μL~1000 μL 0.9% saline solution into each tube, and place the EP tube in a micro mixer at 4℃~10℃ for 10~20 minutes; make a small hole at the bottom of the 0.5 mL EP tube, take out the cotton piece and place it in the 0.5 mL EP tube, and then put the 0.5 mL EP tube with the cotton piece into the original 1.5 mL EP tube;
[0009] S5: centrifugation treatment, placing the 1.5 mL EP tube treated in step S14 in a centrifuge at 4°C and a speed of 10,000-12,000 rpm for 5-10 minutes;
[0010] S6 low temperature storage treatment: After processing in the centrifuge, the nasal secretion solution collected in the 1.5 mL tube was stored in an ultra-low temperature refrigerator at -80℃~-40℃ until testing.
[0011] S7: Collect blood samples, centrifuge them at 3000-3500 rpm, 25-30°C for 10-15 minutes, and collect serum for further analysis;
[0012] S8 After obtaining the nasal secretion solution of step S6 and the serum of step S7, the nasal secretion IgE level and the serum IgE level are detected using the ImmunoCAP 100 system, wherein the IgE value is the sIgE / tIgE value.
[0013] Optionally, in the embodiment, the retention time of the cotton sheet attached to the nasal mucosa in step S2 is 5 minutes;
[0014] Optionally, in the embodiment, the temperature of the drying machine in step S3 is set to 35° C., and the processing time is 2 hours;
[0015] Optionally, in the embodiment, the mixing treatment in step S4 is performed by inverting and mixing at 4° C. for 10 minutes;
[0016] Optionally, in the 1.5 mL EP tubes described in step S4 of the embodiment, 500 μL of 0.9% saline solution is added to each tube;
[0017] Optionally, in step S5 of the embodiment, the centrifuge temperature is set to 4° C., the speed is 12000 rpm, and the processing time is 5 minutes;
[0018] Optionally, the ultra-low temperature refrigerator in step S6 of the embodiment is set to -40°C.
[0019] In a second aspect, an embodiment of the present invention provides a combined analysis method for allergen activity, which analyzes the correlation between seasonal pollen concentration, serum IgE and nasal secretion IgE levels and SAR allergy symptoms and CSMS after obtaining the nasal secretion IgE and serum IgE level values.
[0020] Optionally, the CSMC evaluation includes a symptom evaluation score and a daily medication score, balancing the nose and eye symptoms and the daily medication score with equal weight, and the calculation method is: CSMS=(TNSS+TOSS) / 6+DMS (0-6).
[0021] Optionally, the symptom evaluation score includes nasal and ocular symptom scores, which are scored as 0 to 3 points in order using a four-level graded quantitative score according to severity;
[0022] The total score of nasal symptoms was the sum of the four individual nasal symptoms: nasal itching, runny nose, sneezing, and nasal congestion;
[0023] The total eye symptom score was the sum of the two individual eye symptoms: itchy / red eyes and tearing.
[0024] Optionally, the daily medication score of 0 points indicates no medication; 1 point indicates only the use of antihistamines; 2 points indicates the use of nasal corticosteroids (regardless of whether antihistamines are used); 3 points indicates the use of oral corticosteroids (regardless of whether other drugs are used in combination);
[0025] Optionally, the joint analysis method comprises the following steps:
[0026] Friedman repeated measures rank analysis of variance was used to compare the differences in nasal secretions and serum IgE levels at the four follow-up points at T1;
[0027] T2 used generalized mixed linear models and time series analysis to study the effect of pollen concentration on symptom severity;
[0028] T3 Spearman analysis was used to analyze the correlation between various IgE levels and pollen concentration and symptom severity;
[0029] T4 used causal mediation analysis to clarify the mediating role of changes in IgE levels in nasal secretions during the pollen season between changes in pollen concentration and CSMS differences, and used direct effects, indirect effects, and calculated the proportion of the total effect to evaluate the mediating effect;
[0030] T5 was repeated 1000 times to calculate the confidence interval using the Bootstrap method.
[0031] Optionally, the causal mediation analysis in step T4 is implemented by constructing an analysis model, specifically using a new variable M. If X affects Y by affecting variable M, then M is called a mediating variable. The relationship between the variables can be described by the following regression equation:
[0032] Y = cX + e1 (1)
[0033] Y = aX + e2 (2)
[0034] Y = c'X + bM + e3 (3)
[0035] Where X is the change in total pollen concentration under natural pollen exposure, Y is the change in the severity of seasonal allergic rhinitis symptoms, and M is the change in local IgE.
[0036] In a third aspect, an embodiment of the present invention provides an application of a method for detecting and analyzing allergen activity, specifically an application in the preparation of a kit for evaluating the severity of seasonal allergic rhinitis symptoms, wherein the test samples used in the test are nasal secretions and serum of patients with allergic rhinitis;
[0037] The ImmunoCAP 100 system is used to detect the nasal secretion IgE level and serum IgE level;
[0038] The analysis was a joint analysis of the correlation between seasonal pollen concentration, serum IgE and nasal secretion IgE levels and SAR allergic symptoms and CSMS.
[0039] Compared with the prior art, the present invention has at least the following beneficial effects:
[0040] The present invention has discovered a method for evaluating changes in the severity of allergic rhinitis symptoms by using local IgE levels. By using the IgE levels detected by the method of the present invention and jointly analyzing the correlation between SAR allergic symptoms and CSMS, changes in symptoms of seasonal allergic rhinitis under changes in pollen concentration can be quickly and timely predicted. This method has great clinical and economic value in preparing reagents, kits, test strips or chips for evaluating the severity of seasonal allergic rhinitis symptoms. BRIEF DESCRIPTION OF THE DRAWINGS
[0041] Figure 1 Design diagrams for pollen monitoring and experimental data collection;
[0042] Figure 2 This is a graph showing the effect of pollen concentration (log2 transformed) on symptoms and medication scores based on the GLMM model;
[0043] Figure 3 A- Figure 3F is the comparison of humoral immunoglobulin E levels across seasons and the trend of total pollen concentration with seasons;
[0044] Figure 3 A is the seasonal variation trend of nasal secretion sIgE level and total pollen concentration;
[0045] Figure 3 B is a graph showing seasonal changes in tIgE levels and total pollen concentration in nasal secretions;
[0046] Figure 3 C is a graph showing seasonal changes in nasal secretion sIgE / tIgE levels and total pollen concentration;
[0047] Figure 3 D is the seasonal variation trend of serum sIgE level and total pollen concentration;
[0048] Figure 3 E is the seasonal variation trend of serum tIgE level and total pollen concentration;
[0049] Figure 3 F is the seasonal variation trend of serum sIgE / tIgE levels and total pollen concentration;
[0050] Artemisia sIgE and tIgE were log2-transformed. Q < 0.05; Q < 0.01; Q < 0.001; Q < 0.0001;
[0051] Figure 4 A- Figure 4 F is the correlation analysis diagram between the difference of immunoglobulin E and the change of symptom severity during the pollen season;
[0052] Figure 4 A is the correlation analysis diagram between ΔsIgE and ΔCSMS in nasal secretions during the pollen season;
[0053] Figure 4 B. Correlation analysis of ΔtIgE and ΔCSMS in nasal secretions during the pollen season;
[0054] Figure 4 C Correlation analysis between the ratio of ΔsIgE / ΔtIgE in nasal secretions and ΔCSMS during the pollen season;
[0055] Figure 4 D is the correlation analysis diagram between serum ΔsIgE and ΔCSMS during the pollen season;
[0056] Figure 4 E is the correlation analysis diagram between serum ΔtIgE and ΔCSMS during the pollen season;
[0057] Figure 4 F is the correlation analysis diagram between the ΔsIgE / ΔtIgE ratio and ΔCSMS during the pollen season;
[0058] Figure 5 Path diagram for mediation analysis. DETAILED DESCRIPTION
[0059] In order to make the technical problems, technical solutions and advantages to be solved by the present invention more clear, a detailed description will be given below with reference to the accompanying drawings and specific embodiments.
[0060] Example 1 Patient data and study design
[0061] A total of 25 patients were included in this study, and all patients had to meet the following inclusion criteria: 1) patients aged 18 to 60 years; 2) long-term residents in Beijing; 3) met the diagnostic criteria for AR in ARIA and had (a) two or more nasal symptoms in the past year, including nasal itching, runny nose, sneezing, and nasal congestion; (b) ocular symptoms with or without concurrent onset, manifested as itchy eyes, red eyes, and tearing; (c) symptom onset was significantly seasonal, often occurring in autumn; 4) serum UniCAP test results showed positive Artemisia sIgE (≥ 0.7 kU / L).
[0062] Patients were excluded if they had the following conditions: 1) combined with non-allergic rhinitis, perennial allergic rhinitis, chronic sinusitis with / without nasal polyps, or other diseases that may interfere with SAR symptom scores; 2) combined with other perennial allergens sIgE positive, such as dust mites, animal dander, etc.; 3) ragweed or Humulus serum sIgE level ≥ 3.5 kU / L or higher than Artemisia sIgE; 4) combined with complex diseases such as tumor diseases and autoimmune diseases; 5) women who are preparing for pregnancy or pregnant. This study was approved by the Ethics Committee of Beijing Tongren Hospital, Capital Medical University (TRECKY2021-043). Written informed consent was obtained before the patient participated.
[0063] After signing the informed consent form, the patients entered the 4-month group follow-up study. During this period, 4 follow-up points were set up: early pollen season (follow-up point 1, low pollen concentration); peak pollen season (follow-up point 2, high pollen concentration); pollen fall season (follow-up point 3, medium pollen concentration); pollen season (follow-up point 4). All patients were monitored for daily nasal and eye symptoms and medication use through electronic files during the autumn pollen season. The experimental process is shown in Figure 1 Patients included in the study were allowed to use first-line AR treatment drugs assigned by the investigators for symptomatic treatment during the trial, including oral loratadine tablets, budesonide nasal spray and / or oral methylprednisolone tablets.
[0064] TNSS is the total nasal symptom grading standard, which includes four common nasal symptoms: nasal itching, nasal congestion, sneezing and runny nose. TNSS=2.4+2.4+1.9+2.1=8.8
[0065] TOSS is the total score for eye symptoms (itchy eyes, tearing, and congestion), which includes the two common eye symptoms of tearing and itchy / red eyes. TOSS=1.3+1.9=3.2;
[0066] DMS, daily medication score, DMS=1.6;
[0067] CSMS, combined symptom-drug score, CSMS=(TNSS+TOSS) / 6+DMS=3.6.
[0068] Example 2 Clinical Evaluation Index
[0069] All patients need to evaluate their symptoms and medication daily through an electronic questionnaire. The researchers will distribute electronic questionnaires in the form of QR codes every day. The questionnaires on the same day are required to be submitted to the research center through the backend between 6:30 pm and 8:30 am the next day. The questionnaire uses a symptom-drug joint score to balance the nasal and eye symptoms and daily medication scores with equal weight. Symptoms include nasal itching, runny nose, sneezing, nasal congestion, itchy / red eyes, and tearing. The severity is graded and quantified using a four-level score, which is scored from 0 to 3 points: 0 points for no such symptom; 1 point for mild; 2 points for moderate; 3 points for severe. Daily medication 0 points means no medication; 1 point means only antihistamines; 2 points for nasal corticosteroids (regardless of whether antihistamines are used); 3 points for oral corticosteroids (regardless of whether other drugs are used in combination). The symptom-drug joint score is the sum of the mean symptom score and the medication score. The higher the score, the more severe the symptoms.
[0070] Example 3 Sample detection
[0071] Acquisition of local IgE and serum IgE:
[0072] Local IgE: Before collecting nasal secretions, ensure that the subjects are in a resting state and comfortable environment; place two cotton pieces (Punot, China) (3×0.8×0.1 cm) in the left and right middle nasal passages of the subjects with forceps, adhere to the nasal mucosa, and leave for 5 minutes; remove the cotton pieces from the nasal cavity and place them in a tray with grooves, and mark them; preheat the dryer to 35°C, place the tray in the dryer and dry for 2 hours; after drying, place the cotton pieces in 1.5 mL EP tubes, add 500 μL of 0.9% saline solution to each tube, and place the EP tube in a micromixer at 4°C and mix them upside down for 10 minutes; make a small hole at the bottom of the 0.5 mL EP tube, take out the cotton pieces and place them in the 0.5 mL EP tube, and be careful to avoid spilling during operation. Then place the 0.5 mL EP tube containing the cotton pieces in the original 1.5 mL EP tube. Centrifuge at 4°C, 12,000 rpm for 5 minutes; after centrifugation, the nasal secretion solution collected in the 1.5 mL tube was stored in a -80°C refrigerator until detection.
[0073] Serum IgE: After the patient's blood sample was centrifuged (3000 rpm, room temperature, 10 minutes), the serum was collected for further analysis.
[0074] IgE detection: Local IgE and serum IgE were detected using the ImmunoCAP 100 system (Pharmacia, Uppsala, Sweden).
[0075] Statistical methods: Specifically, statistical analysis was performed using R software version 4.1.2, and data were reported as mean (standard deviation) or median (interquartile range). Daily means of six individual symptoms, medication scores, and combined scores were calculated. Due to the skewed distribution of the data, IgE levels were logarithmized.
[0076] Friedman repeated measures rank analysis of variance was used to compare the differences in nasal secretion and serum IgE levels at the four follow-up points.
[0077] Generalized linear mixed models (GLMM) and time series analysis were used to investigate the effect of pollen concentration on symptom severity.
[0078] The correlations between various IgE levels and pollen concentrations and symptom severity were compared using Spearman analysis.
[0079] In addition, causal mediation analysis was used to clarify the mediating role of changes in IgE levels in nasal secretions during the pollen season between changes in pollen concentration and CSMS differences (V2 - V1 and V3 - V2). The mediation effect was evaluated by direct effect (DE), indirect effect (IE) and calculation of the total effect ratio [IE / (IE+DE)].
[0080] The confidence intervals (CI) were calculated by bootstrap method with 1000 repetitions.
[0081] Example 4 Sample test results
[0082] We further verified the temporal changes between pollen concentration and symptom scores using generalized linear mixed models and found that the combined symptom and medication scores of SAR patients increased with increasing pollen concentration. This trend was also verified in single symptom scores and daily medication scores.
[0083] like Figure 2 As shown, pollen concentration showed a significant effect on all response variables included in the analysis (Q < 0.0001). The significance was assessed using a two-sided Wald test. Solid circles represent statistically significant parameter estimates (Q < 0.0001), and 95% confidence intervals are also shown. ACF was used to calculate the time effect of pollen concentration on the day of symptoms ± 7 days. Among them, the total score of nasal symptoms and the combined score of symptom medication were observed to have the highest correlation with pollen exposure on the same day, and the other indicators were lagged by one day.
[0084] We analyzed the dynamic changes of IgE levels in body fluids under natural pollen exposure by comparing IgE levels in peripheral blood and nasal secretions at each follow-up point.
[0085] In nasal secretions, Artemisia sIgE peaked during the peak pollen season (V2) and was significantly higher than that during the early pollen season (V1) ( Figure 3 A, Q < 0.05). A downward trend in sIgE levels was observed during the pollen fall period (V3) and the non-pollen season (V4), but the difference from the peak period was not statistically significant. No statistical difference was observed in the tIgE levels of nasal secretions in different time periods ( Figure 3 B). Comparison of nasal secretion sIgE / tIgE observed an expression pattern consistent with sIgE, with more significant cross-sectional differences ( Figure 3C, V1 to V2, Q < 0.001; V2 to V3, Q < 0.05). To further explore the relationship between the dynamic changes of nasal secretion IgE and pollen concentration, the Spearman correlation test was performed. Only the ratio of sIgE / tIgE in nasal secretions (Spearman correlation coefficient r = 0.415, Q < 0.01) was positively correlated with the total pollen concentration.
[0086] In serum, Artemisia sIgE was significantly higher in the pollen fall period (V3) than in the pollen early period (V1) and pollen peak period (V2) ( Figure 3 D, V2 vs. V3, Q < 0.05; V1 vs. V3, Q < 0.0001). Meanwhile, in the non-pollen season (V4), sIgE levels did not return to the levels of the early pollen season (Q < 0.0001). Serum tIgE also peaked during the pollen fall period ( Figure 3 -E, Q <0.05). The expression pattern of serum sIgE / tIgE was different from that of sIgE, and showed significant differences compared with the previous follow-up point in the non-pollen season ( Figure 3 F, V1 vs. V4, Q < 0.05; V2 vs. V4, Q < 0.001). No obvious monotonic trend was observed between serum IgE levels and pollen concentration. Considering the specific effect of Artemisia pollen, we repeated the above analysis between Artemisia pollen concentration and IgE levels, and the conclusions obtained were consistent with those of total pollen concentration.
[0087] Therefore, Artemisia sIgE and sIgE / tIgE in nasal secretions of SAR patients reached the highest values during the peak of the pollen season, among which the nasal secretion sIgE / tIgE reaction showed better timeliness and had a significant positive correlation with the change of pollen concentration. However, the peak time of serum IgE level and pollen concentration was inconsistent, lagging behind the change of pollen concentration.
[0088] We further analyzed whether changes in nasal IgE levels could serve as a quantifiable biomarker to track changes in SAR symptom severity during the pollen season.
[0089] The change in each patient's CSMS score corresponded to the change in their IgE level during the pollen season (expressed as Δ=V2 - V1, V3 -V2). Spearman correlation analysis compared the correlation between ΔCSMS and body fluid ΔIgE levels, and the Spearman r coefficient was annotated. Bonferroni correction was performed for multiple hypothesis testing, and the corrected P value was defined as Q. Spearman correlation analysis showed that Δnasal secretion sIgE and sIgE / tIgE were significantly positively correlated with ΔCSMS ( Figure 4 A and Figure 4C (r = 0.424, Q < 0.05; r = 0.444, Q < 0.01). In serum, only Δserum sIgE / tIgE showed a significant negative correlation with ΔCSMS ( Figure 4 -F) (r = 0.385, Q < 0.05). The seasonal changes of other IgE variables were not significantly correlated with ΔCSMS.
[0090] Based on the above analysis results, only the changes in nasal secretions sIgE / tIgE showed a significant correlation trend with both pollen concentration and SAR symptom changes. In order to better understand the relationship between the three, we conducted a mediation analysis to analyze the mediating effect of nasal secretions ΔsIgE / tIgE between changes in pollen concentration and changes in SAR symptoms during the pollen season. The analysis model is as follows:
[0091] A new variable M is used. If X affects Y by affecting variable M, then M is called a mediating variable. The following regression equation can be used to describe the relationship between the variables.
[0092] Y = cX + e1 (1)
[0093] Y = aX + e2 (2)
[0094] Y = c'X + bM + e3 (3)
[0095] Where X is the change in total pollen concentration under natural pollen exposure, Y is the change in the severity of seasonal allergic rhinitis symptoms, and M is the change in local IgE.
[0096] like Figure 5 The results showed that Δ nasal secretion sIgE / tIgE significantly mediated the effect of pollen on CSMS in SAR patients, with a mediating effect of β = 0.177, 95% CI, P < 0.01, accounting for 27.3% of the total effect. The direct effect of Δ pollen and Δ CSMS β = 0.471, 95% CI, P < 0.0001; the total effect β = 0.648, 95% CI, P < 0.0001.
[0097] Example 5 Verification and Analysis Model
[0098] Based on the screening data set, it was found that the changes in sIgE / tIgE in nasal secretions showed a significant correlation trend with the changes in pollen concentration and SAR symptoms, and a mediation effect analysis was performed. The analysis model was the same as in Example Formulas (1)-(3): The placebo group in another clinical study, which was a group of SAR patients, was followed up regularly during the pollen season, and the severity of SAR symptoms was recorded and nasal secretion IgE was tested at different time points, which was consistent with the data type of the screening set.
[0099] The mediation effect analysis was performed on the validation data set, and the regression equation calculated based on the validation data set is as follows:
[0100] Y = 0.007627X-1.691545 (4)
[0101] M = -0.000111X-0.10440 (5)
[0102] Y= 0.006682X-8.49262M-1.780250 (6)
[0103] The results were as follows: Δ nasal secretion sIgE / tIgE significantly mediated the effect of pollen on symptom scores of SAR patients, with a mediating effect of β = 0.062, 95% CI, P < 0.01, accounting for 12.4% of the total effect. The direct effect of Δ pollen and Δ symptom score was β = 0.436, 95% CI, P < 0.0001; the total effect was β = 0.498, 95% CI, P < 0.0001.
[0104] The above is a preferred embodiment of the present invention. It should be pointed out that for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the principles of the present invention. These improvements and modifications should also be regarded as the scope of protection of the present invention.
Claims
1. A method for preparing a solution for detecting allergen activity, characterized in that: The following steps are involved: S1 Collection preparation: Before collecting nasal secretions, ensure that the subject is in a resting state and comfortable environment; S2 collection and processing: two cotton pads were placed in the left and right middle nasal passages of the subjects with forceps, attached to the nasal mucosa, and left for 5 to 10 minutes; S3 drying treatment: take the cotton pad out of the nasal cavity and place it in a tray with grooves, mark it; place the tray in a dryer set at 35℃~40℃ for 2~2.5 hours; S4 centrifugal pretreatment, after drying, put the cotton pieces into 1.5 mL EP tubes, add 500 μL~1000 μL 0.9% saline solution into each tube, and place the EP tube in a micro mixer at 4℃~10℃ for 10~20 minutes; make a small hole at the bottom of the 0.5 mL EP tube, take out the cotton piece and place it in the 0.5 mL EP tube, and then put the 0.5 mL EP tube with the cotton piece into the original 1.5 mL EP tube; S5: centrifugation treatment, placing the 1.5 mL EP tube treated in step S14 in a centrifuge at 4°C and a speed of 10,000-12,000 rpm for 5-10 minutes; S6 cryopreservation treatment: After processing in the centrifuge, the nasal secretion solution collected in the 1.5 mL tube was stored in an ultra-low temperature refrigerator at -80℃~-40℃ until testing; Blood samples were collected at S7°C and centrifuged at 3000-3500 rpm, 25-30°C for 10-15 minutes, and serum was collected for further analysis; S8 After obtaining the nasal secretion solution of step S6 and the serum of step S7, the nasal secretion IgE level and the serum IgE level are detected using the ImmunoCAP 100 system, wherein the IgE value is the sIgE / tIgE value.
2. A combined analysis method for allergen activity, characterized in that: After obtaining the nasal secretion IgE and serum IgE level values as described in claim 1, the correlation between seasonal pollen concentration, serum IgE and nasal secretion IgE levels and SAR allergy symptoms and CSMS is analyzed.
3. The analysis method according to claim 2, characterized in that The CSMC evaluation includes a symptom evaluation score and a daily medication score, balancing nose and eye symptoms and daily medication scores with equal weights, and is calculated as follows: CSMS=(TNSS+TOSS) / 6+DMS (0-6).
4. The analysis method according to claim 3, characterized in that The symptom evaluation score includes nasal and eye symptom scores, which are graded and quantified into four levels according to severity, ranging from 0 to 3 points; The total score of nasal symptoms was the sum of the four individual nasal symptoms: nasal itching, runny nose, sneezing, and nasal congestion; The total eye symptom score was the sum of the two individual eye symptoms: itchy / red eyes and tearing.
5. The analysis method according to claim 3, characterized in that The daily medication score of 0 indicates no medication; 1 indicates only antihistamine use; 2 indicates use of nasal corticosteroids (regardless of whether antihistamines are used); and 3 indicates use of oral corticosteroids (regardless of whether other drugs are used in combination).
6. The analysis method according to claim 2, characterized in that The specific steps include: Friedman repeated measures rank analysis of variance was used to compare the differences in nasal secretions and serum IgE levels at the four follow-up points at T1; T2 used generalized mixed linear models and time series analysis to study the effect of pollen concentration on symptom severity; T3 Spearman analysis was used to analyze the correlation between various IgE levels and pollen concentration and symptom severity; T4 used causal mediation analysis to clarify the mediating role of changes in IgE levels in nasal secretions during the pollen season between changes in pollen concentration and CSMS differences, and used direct effects, indirect effects, and calculated the proportion of the total effect to evaluate the mediating effect; T5 was repeated 1000 times to calculate the confidence interval using the Bootstrap method.
7. The analysis method according to claim 6, characterized in that The causal mediation analysis in step T4 is implemented by constructing an analysis model, specifically using a new variable M and using the following regression equation to describe the relationship between the variables: Y = cX + e1 (1) Y = aX + e2 (2) Y = c'X + bM + e3 (3) Where X is the change in total pollen concentration under natural pollen exposure, Y is the change in the severity of seasonal allergic rhinitis symptoms, and M is the change in local IgE.
8. Application of a method for detecting and analyzing allergen activity, characterized in that: The invention is used in the preparation of a kit for evaluating the severity of seasonal allergic rhinitis symptoms, wherein the test samples used in the test are nasal secretions and serum of patients with allergic rhinitis.
9. The use according to claim 8, characterized in that: The ImmunoCAP 100 system was used to detect the nasal secretion IgE level and serum IgE level.
10. The use according to claim 8, characterized in that: The analysis was a joint analysis of the correlation between seasonal pollen concentration, serum IgE and nasal secretion IgE levels and SAR allergic symptoms and CSMS.
Citation Information
Patent Citations
Method of preparing standard serum mixture for determining activity of an allergen and application of the serum mixture
CN101595389A
Health tea having adjuvant therapy effect on rhinitis, and preparation method and detection method thereof
CN105230836A
Nasal secretion acquisition retention device, acquisition retention processing method, and applications of nasal secretion acquisition retention device and acquisition retention processing method
CN108801693A
Nasal secretion total IgE colloidal gold detection card, kit and application thereof
CN110531089A
Application of asparagine in prediction or diagnosis of type 2 diabetes mellitus
CN115356471A
